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Summary Lichen planus and lupus erythematosus may occur as an overlap syndrome. Here we report the
clinical characteristics of a 49-year-old man with palmoplantar lichen planus and lupus 
erythematosus. He showed a remarkable clinical response to treatm ent with acitretin, which 
resulted in prolonged remission of the disorder.
Lichen planus and lupus erythem atosus may coexist
1 C
in some patients, and have been treated by topical 
or intralesional corticosteroids, antim alarial drugs 
and oral corticosteroids, although the results are
r
inconsistent.“’ Common aetiopathological pathways
have been suggested, but the causal relationship is 
unknow n.
The aromatic retinoids, etretinate and acitretin, allow 
successful treatm ent of patients with keratinization 
disorders such as psoriasis, the ichthyoses, and geno- 
dermatoses such as Darier’s disease/ Oral lichen 
planus improves with oral etretinate (75 mg daily), 
and both etretinate and acitretin have been used in 
patients with recalcitrant discoid chronic or subacute 
lupus erythematosus. '11 As far as we know, acitretin 
has not been reported as a treatment for palmoplantar 
lichen planus or for the lichen planus/lupus erythema­
tosus overlap syndrome. In this report we describe the 
manifestations of the lichen planus/lupus erythema­
tosus overlap syndrome (in a patient with involvement 
of the palms and soles) and report the response to 
treatm ent with acitretin.
9
Case report
A 49-year-old m an presented with a 6-month history of 
itchy, non-painful lesions on the back, on the arms, and 
on the dorsal and palmar aspects of the hands and feet. 
He had been treated with topical clobetasol propionate 
for several weeks without success. He gave a past 
history of coronary artery disease (for which he received 
isosorbide dinitrate), arthralgia (for which he took 
ibuprofen), and he had had recurrent episodes of epi­
scleritis. Examination showed well-demarcated erythe­
matous squamous plaques, some showing atrophy and
Wickham’s striae, on the back, arms, hands (palmar 
and dorsal surfaces) and feet (plantar and dorsal sur­
faces) (Fig. 1). The lesions on the hands and arms 
showed a violaceous erythema and there was slight 
hyperpigmentation of the lesions on the back. The 
palmar eruption was partly erosive with some papular 
and hyperkeratotic changes. No facial involvement was 
noted. He was obese blit had no signs of joint disease. 
Routine haematological and biochemical studies were 
normal (apart from an erythrocyte sedimentation rate 
of 30 mm/first hour). Antinuclear antibodies and 
rheumatoid factor were not detected and joint X-rays 
were normal. A skin biopsy, taken from lesions from the 
back, showed a partly atrophic epidermis with hydropic 
degeneration of the basal layer (Fig. 2), with hyper­
keratosis, slight parakeratosis and Civatte bodies within 
the epidermis. In the upper dermis there was a peri­
vascular, mainly lymphocytic, inflammatory infiltrate 
which showed a perifollicular localization. The granular
layer of the epidermis was of varis
Immunofluorescence on of lesionai
showed granular immunoglobulin (Ig) M deposition at 
the dermo-epidermal junction with some 03 deposits at 
the transition of epidermis to dermis, but no reaction for 
IgG, IgA or Clq.
The clinical and histological features were of lichen 
planus and discoid lupus erythematosus and, in view of 
this, a diagnosis of the lichen planus/lupus erythem a­
tosus overlap syndrome was made. In view of the non­
response to topical corticosteroids and the extensive 
involvement, acitretin was commenced at 3 5 mg 
daily, in addition to continuance of the topical steroids. 
The acitretin was increased to 50 mg daily and, after 12 
weeks, the lesions had flattened and some clearance 
was noted. The dose of acitretin was cautiously reduced
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Fig. 3. Back (a) and palm (b), following 
acttretin therapy.
lupus erythematosus and lichen planus are immuno- 
logically mediated and, although it is well accepted that 
lupus erythematosus is an inflammatory disorder, the 
pathogenesis is obscure. The lesions of lupus erythema­
tosus may result from immune complex-mediated 
injury,12-15 but might also be the result of a cell- 
mediated attack on the epidermis comparable with 
graft-versus-host disease. Ul~18 Lichen planus is likewise
logical features of an interphase dermatitis seen in both 
disorders. In addition, both conditions show changes in 
keratinization, with hyperproliferation in the early 
phases, and the presence of atrophy when the 
pilosebaceous unit is involved.
The pathogenetic features of lupus erythematosus
j may be an 
an immune
and lichen planus mean that 
effective treatment. Retinoids can
thought to be immunologically mediated,19,20 with a modulatory effect, and are known
characteristic feature, and an epidermal antigen which 
may elicit a T-cell response has been postulated.
Both lichen planus and discoid lupus erythematosus
disorders 
hyperproliferation.
of
2 1-2 3
keratinization which
is an increase m
or an e"
16 (associated with 
slate of the
dermis), in addition to the normal pattern of keratin 
10, which is a marker for early differentiation. In
entiation such as involucrin and 
increased, and similar studies have recently been
performed in lichen and
J.Peperkamp, personal communication). In lichen 
planus lesions, keratins 16 and 6 are prominent in 
the suprabasal compartment, keratin 10 is reduced, 
and involucrin is expressed in the whole suprabasal 
compartment. Hence, some pathogenetic mechanisms 
seem to be common to both lichen planus and lupus
inerythematosus, and this is ah
gamma- 
md to block
are also to the
v, , 2 7  increase
s in norme
50
synthesis of polyamines, important in regulating cell
and retinoids, both in vitro and in vivo,
J2 , ninhibit transcription of 
enzyme crucial to cross-linking of involucrin which is
the main constituent of corneocyte
Retinoids modulate the expression of keratins 4, 10, 
13, 16 and 19. 1 Thus there are several theoretical 
reasons why retinoids may have an effect in
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tretin in a patient with the lichen planus/lupus 
erythematosus overlap syndrome. The dose of acitretin 
was increased from 35 to 50 mg daily and, once benefit 
was obtained, the dose was decreased with the con­
tinuance of benefit and only minimal side-effects of 
dryness of the skin and mucosae. Acitretin offers a 
therapeutic alternative to patients w ith the lichen 
planus/lupus erythematosus overlap syndrome who 
are recalcitrant to treatment with topical corticosteroids
A *
and antimalarial drugs.
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